Back to Search
Start Over
CC motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells.
- Source :
-
Hepatobiliary & pancreatic diseases international : HBPD INT [Hepatobiliary Pancreat Dis Int] 2020 Oct; Vol. 19 (5), pp. 440-448. Date of Electronic Publication: 2020 Jan 03. - Publication Year :
- 2020
-
Abstract
- Background: Liver cirrhosis results from many forms of chronic damage, characterized by accumulation of extracellular matrix. The present study aimed to explore a potential non-invasive biomarker and its mechanism in the progression of liver cirrhosis.<br />Methods: Gene Expression Omnibus (GEO) dataset (GSE15654, n = 216) was analyzed to screen genes associated with progression of liver cirrhosis. A total of 181 plasma samples, including healthy control (HC, n = 20), chronic hepatitis B (CHB, n = 77) and HBV-related liver cirrhosis (LC, n = 84), were enrolled for validation. In vitro and in vivo experiments were employed for the mechanistic investigation.<br />Results: GEO dataset analysis showed that relatively low mRNA-expression of CC motif chemokine ligand 16 (CCL16) was associated with elevated Child-Pugh score (P = 0.034) and worse prognosis (P = 0.025). Plasma CCL16 level decreased in a stepwise pattern, with a median concentration of 10.29, 6.57 and 4.47 ng/mL in the HC, CHB and LC groups, respectively (P<0.001). Low plasma CCL16 was significantly related to hepatic dysfunction both in the CHB and LC groups (P<0.05). Combination of CCL16 and ALT showed improved distinguishing capability for LC compared to either alone. In vitro, CCL16 expression was downregulated by lipopolysaccharide and hypoxia. Overexpression of CCL16 from human normal liver cell line (LO2) reduced the extracellular matrix associated proteins (Col1 and Col4) in human hepatic stellate cell line (LX-2). In vivo, the pathological feature of cirrhosis was alleviated by the hepatocyte-specific expression of CCL16.<br />Conclusions: CCL16 could be a feasible plasma marker to predict the occurrence and progression of liver cirrhosis. CCL16 might impact liver cirrhosis through inactivating hepatic stellate cells.<br />Competing Interests: Competing interest No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.<br /> (Copyright © 2020. Published by Elsevier B.V.)
- Subjects :
- Adult
Animals
Biomarkers metabolism
Case-Control Studies
Cell Line
Chemokines, CC genetics
Collagen Type I metabolism
Collagen Type IV metabolism
Databases, Genetic
Female
Hepatic Stellate Cells pathology
Hepatocytes pathology
Humans
Liver pathology
Liver Cirrhosis genetics
Liver Cirrhosis pathology
Liver Cirrhosis, Experimental genetics
Liver Cirrhosis, Experimental pathology
Male
Mice, Inbred BALB C
Middle Aged
Prognosis
Chemokines, CC metabolism
Hepatic Stellate Cells metabolism
Hepatocytes metabolism
Liver metabolism
Liver Cirrhosis metabolism
Liver Cirrhosis, Experimental metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1499-3872
- Volume :
- 19
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Hepatobiliary & pancreatic diseases international : HBPD INT
- Publication Type :
- Academic Journal
- Accession number :
- 31948840
- Full Text :
- https://doi.org/10.1016/j.hbpd.2019.12.006